Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis
- PMID: 30227941
- DOI: 10.1016/j.ahj.2018.08.007
Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis
Abstract
Warfarin, a vitamin K antagonist, is associated with systemic vascular calcification. We evaluated whether rivaroxaban (a direct oral factor Xa inhibitor with no interaction with vitamin K) will slow the progression in coronary plaque volumes compared with warfarin in patients with nonvalvular atrial fibrillation using coronary computed tomography angiography.
Copyright © 2018 Elsevier Inc. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
